Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing in the development of innovative therapies for serious diseases. Headquartered in Boston, Massachusetts, Vertex focuses on pioneering treatments for cystic fibrosis and advancing research in genetic and rare diseases, leveraging cutting-edge science to improve patient outcomes worldwide.

Shares of the biotechnology company have underperformed the broader market over the past year. VRTX has gained 11.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 22.8%. However, in 2025, VRTX’s stock rose 17.2%, compared to SPX’s 4.5% rise on a YTD basis.